In a phase III randomized, double-blind, placebo-controlled MONALEESA-2 study, 668 HR-positive/HER2-negative breast cancer patients with advanced breast cancer were randomized to receive either ribociclib plus letrozole or placebo plus letrozole [357]. This evidence concerns the gene ERBB2 and breast cancer.